Sabatier, R.; Pierga, J.-Y.; Curé, H.; Abulnaja, R.; Lambaudie, E.; Bidard, F.-C.; Extra, J.-M.; Sfumato, P.; Gonçalves, A.
Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers 2021, 13, 140.
https://doi.org/10.3390/cancers13010140
AMA Style
Sabatier R, Pierga J-Y, Curé H, Abulnaja R, Lambaudie E, Bidard F-C, Extra J-M, Sfumato P, Gonçalves A.
Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers. 2021; 13(1):140.
https://doi.org/10.3390/cancers13010140
Chicago/Turabian Style
Sabatier, Renaud, Jean-Yves Pierga, Hervé Curé, Rakan Abulnaja, Eric Lambaudie, François-Clément Bidard, Jean-Marc Extra, Patrick Sfumato, and Anthony Gonçalves.
2021. "Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial" Cancers 13, no. 1: 140.
https://doi.org/10.3390/cancers13010140
APA Style
Sabatier, R., Pierga, J.-Y., Curé, H., Abulnaja, R., Lambaudie, E., Bidard, F.-C., Extra, J.-M., Sfumato, P., & Gonçalves, A.
(2021). Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers, 13(1), 140.
https://doi.org/10.3390/cancers13010140
